We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Five-Gene Signature Predicts Survival from Renal Cell Carcinoma

By LabMedica International staff writers
Posted on 20 Mar 2019
Papillary renal cell carcinomas include type 1 lesions, which are characterized by small cells in single layers and scanty cytoplasm and type 2 lesions, which are distinguished by larger cells, pseudo-stratified nuclei, and voluminous eosinophilic cytoplasm.

Though the exact cause of papillary renal cell carcinoma is unknown, smoking, obesity, and genetic predisposition conditions such as hereditary leiomyomatosis and renal cell cancer may contribute to the development of this type of cancer. More...
It accounts for about 10% to 15% of all renal cell carcinomas.

Urologists at the Qilu Hospital of Shandong University (Jinan, China) and their associates investigated the gene expression changes in papillary renal cell carcinoma (pRCC) and screen several genes and associated pathways of pRCC progression. They downloaded the pRCC RNA sequencing (RNA-seq) data set from The Cancer Genome Atlas (TCGA). They identified the differentially expressed messenger RNA (mRNA) between cancer and normal tissues and performed annotation of differentially expressed mRNAs to figure out the functions and pathways they were enriched in. Then, they constructed a risk score that relied on 5-mRNAs.

Based on differentially expressed gene in high-risk cases, the investigators found five survival-related genes, CCNB2, IGF2BP3, KIF18A, PTTG1, and BUB1, that could distinguish 53 high-risk pRCC patients from 89 low-risk patients in a subsequent validation analysis. The study revealed the 5-mRNA expression profile and the potential function of a single mRNA as a prognostic target for papillary renal cell carcinoma.

The authors concluded that by performing a comprehensive analysis for differentially expressed mRNA profiles and corresponding clinical information, the study demonstrated that 5-mRNA signature was a potential diagnostic marker in pRCC, and was an independent prognostic factor in pRCC patients. This signature has a lot of potential prognostic and therapeutic implications for the pRCC patient management. The study was published on March 1, 2019, in the journal PLoS ONE.

Related Links:
Qilu Hospital of Shandong University


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Specimen Radiography System
TrueView 200 Pro
New
PSA Assay
CanAg PSA EIA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.